Deciphering the Role of Glutamate Signaling in Glioblastoma Multiforme: Current Therapeutic Modalities and Future Directions-Reference-Cited by-同舟云学术

Deciphering the Role of Glutamate Signaling in Glioblastoma Multiforme: Current Therapeutic Modalities and Future Directions

Published:2020-10-26 Issue:37 Volume:26 Page:4777-4788
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Mollazadeh Hamid¹^ORCID,Mohtashami Elmira²^ORCID,Mousavi Seyed H.³^ORCID,Soukhtanloo Mohammad⁴^ORCID,Vahedi Mohammad M.⁵^ORCID,Hosseini Azar²,Afshari Amir R.¹^ORCID,Sahebkar Amirhossein⁶^ORCID

Affiliation:

1. Department of Physiology and Pharmacology, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran

2. Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran

3. Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

4. Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5. Department of Pharmacology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

6. Halal Research Center of IRI, FDA, Tehran, Iran

Abstract

As the most popular intrinsic neoplasm throughout the brain, glioblastoma multiforme (GBM) is resistant to existing therapies. Due to its invasive nature, GBM shows a poor prognosis despite aggressive surgery and chemoradiation. Therefore, identifying and understanding the critical molecules of GBM can help develop new therapeutic strategies. Glutamatergic signaling dysfunction has been well documented in neurodegenerative diseases as well as in GBM. Inhibition of glutamate receptor activation or extracellular glutamate release by specific antagonists inhibits cell development, invasion, and migration and contributes to apoptosis and autophagy in GBM cells. This review outlines the current knowledge of glutamate signaling involvement and current therapeutic modalities for the treatment of GBM.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference132 articles.

1. Bailly C.; Vidal A.; Bonnemaire C.; Potential for nuclear medicine therapy for glioblastoma treatment. Front Pharmacol 2019,10,772

2. Tavana E.; Mollazadeh H.; Mohtashami E.; Quercetin: A promising phytochemical for the treatment of glioblastoma multiforme. Biofactors 2019

3. Soukhtanloo M.; Mohtashami E.; Maghrouni A.; Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway. Pharmacol Rep 2020,72(2),285-295

4. Afshari A.R.; Mollazadeh H.; Mohtashami E.; Protective role of natural products in glioblastoma multiforme: A focus on nitric oxide pathway. Curr Med Chem 2020

5. Akhavan D.; Pourzia A.L.; Nourian A.A.; De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 2013,3(5),534-547

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glioblastoma: A molecular insight into current discoveries and treatment directions;Medical Journal of Cell Biology;2024-07-01

2. Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study;AVICENNA J PHYTOMEDI;2024

3. Current state of immune checkpoints therapy for glioblastoma;Heliyon;2024-01

4. Psidium guajava induces cytotoxicity in human malignant glioblastoma cell line: Role of reactive oxygen species;Toxicology in Vitro;2023-06

5. The Potential Therapeutic Impact of Metformin in Glioblastoma Multiforme;Current Medicinal Chemistry;2023-02